The country is clearly shaping its legislation to promote access to medicines by fostering generic production. INDIA'S approach to the revision of its Patents Act in 2005 is a clear example of a country shaping its legislation to promote access to medicines by fostering generic production. Although World Trade Organisation (WTO) rules made it mandatory for India to put in place a patent regime for medicines by 2005, nothing obliges...
More »SEARCH RESULT
Total Matching Records found : 7448
Microfinance institutions escape charge of abetting suicide of clients-M Suchitra
In 2010, Andhra Pradesh witnessed a series of suicides. These were not cases of farmers' suicides—a regular occurrence in the state which continues to be in the grip of an agrarian crisis. The victims in these cases happened to be the poorest of the poor; most of them illiterate dalits and adivasis. The first information reports (FIRs) of the police reveal that most of the suicides were due to coercive...
More »Posco in limbo-V Venkatesan
The National Green Tribunal's decision to suspend the environmental clearance given to Posco vindicates the project's critics. ON March 30, the Principal Bench of the newly formed National Green Tribunal (NGT) delivered a momentous decision suspending the environmental clearance (EC) given to the South Korean transnational corporation, Posco, to set up an integrated steel plant at Paradip in Odisha's Jagatsinghpur district. The former Union Minister for Environment and Forests, Jairam...
More »Patent to plunder -Amit Sengupta
India's efforts to produce and supply life-saving drugs at affordable prices face challenges from multinational companies trying to “evergreen” their patents. THE average life expectancy across the globe has increased from around 30 years a century ago to over 65 years today. This has been made possible in large part by modern medicine. Never before in history have humans had access to such an array of medicines and devices to...
More »A welcome first -TK Rajalakshmi
Industry reacts with caution to the grant of a compulsory licence to Natco, but cancer patients welcome it and hope for many more. THE first compulsory licence (CL) issued by the Indian patent office, to the local drug manufacturer Natco Pharma Ltd to sell the generic version of Bayer AG's anti-cancer drug Nexavar, has led to varied reactions. The landmark decision has also raised concerns about the outcome of cases...
More »
